Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 241

1.

IBC's 23rd Annual Antibody Engineering, 10th Annual Antibody Therapeutics international conferences and the 2012 Annual Meeting of The Antibody Society: December 3-6, 2012, San Diego, CA.

Klöhn PC, Wuellner U, Zizlsperger N, Zhou Y, Tavares D, Berger S, Zettlitz KA, Proetzel G, Yong M, Begent RH, Reichert JM.

MAbs. 2013 Mar-Apr;5(2):178-201. doi: 10.4161/mabs.23655.

2.

IBC's 23rd Antibody Engineering and 10th Antibody Therapeutics Conferences and the Annual Meeting of The Antibody Society: December 2-6, 2012, San Diego, CA.

Marquardt J, Begent RH, Chester K, Huston JS, Bradbury A, Scott JK, Thorpe PE, Veldman T, Reichert JM, Weiner LM.

MAbs. 2012 Nov-Dec;4(6):648-52. doi: 10.4161/mabs.22221. Epub 2012 Sep 24.

3.

Guidelines for information about therapy experiments: a proposal on best practice for recording experimental data on cancer therapy.

González-Beltrán AN, Yong MY, Dancey G, Begent R.

BMC Res Notes. 2012 Jan 6;5:10. doi: 10.1186/1756-0500-5-10.

4.

Establishing a knowledge trail from molecular experiments to clinical trials.

Yong MY, González-Beltrán A, Begent R.

N Biotechnol. 2011 Sep;28(5):464-80. doi: 10.1016/j.nbt.2011.03.016. Epub 2011 Apr 5. Review.

PMID:
21473938
5.

Immunohistochemical expression of VEGF predicts response to platinum based chemotherapy in patients with epithelial ovarian cancer.

Siddiqui GK, Maclean AB, Elmasry K, Wong te Fong A, Morris RW, Rashid M, Begent RH, Boxer GM.

Angiogenesis. 2011 May;14(2):155-61. doi: 10.1007/s10456-010-9199-4. Epub 2011 Jan 9.

PMID:
21221762
6.

Best use of experimental data in cancer informatics.

Yong M, Begent R.

Future Oncol. 2010 Oct;6(10):1551-62. doi: 10.2217/fon.10.108. Review. Erratum in: Future Oncol. 2011 Jan;7(1):154.

PMID:
21062155
7.

Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours.

Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T.

Br J Cancer. 2010 Mar 30;102(7):1106-12. doi: 10.1038/sj.bjc.6605618. Epub 2010 Mar 16.

8.

Observations and hypothesis on an individual patient topically treated for capecitabine-induced Palmar-Plantar syndrome.

Gafson AR, Goodkin O, Begent R.

BMJ Case Rep. 2010 Nov 9;2010. pii: bcr0420102869. doi: 10.1136/bcr.04.2010.2869.

9.

A Phase I Clinical Trial of CHT-25 a 131I-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma.

Dancey G, Violet J, Malaroda A, Green AJ, Sharma SK, Francis R, Othman S, Parker S, Buscombe J, Griffin N, Chan PS, Malhotra A, Woodward N, Ramsay A, Ross P, Lister TA, Amlot P, Begent R, McNamara C.

Clin Cancer Res. 2009 Dec 15;15(24):7701-7710.

10.

Nanoparticles functionalized with recombinant single chain Fv antibody fragments (scFv) for the magnetic resonance imaging of cancer cells.

Vigor KL, Kyrtatos PG, Minogue S, Al-Jamal KT, Kogelberg H, Tolner B, Kostarelos K, Begent RH, Pankhurst QA, Lythgoe MF, Chester KA.

Biomaterials. 2010 Feb;31(6):1307-15. doi: 10.1016/j.biomaterials.2009.10.036. Epub 2009 Nov 4.

PMID:
19889453
11.

From practice guidelines to clinical decision support: closing the loop.

Fox J, Patkar V, Chronakis I, Begent R.

J R Soc Med. 2009 Nov;102(11):464-73. doi: 10.1258/jrsm.2009.090010. No abstract available.

12.

Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake.

Dearling JL, Flynn AA, Qureshi U, Whiting S, Boxer GM, Green A, Begent RH, Pedley RB.

Nucl Med Biol. 2009 Nov;36(8):883-94. doi: 10.1016/j.nucmedbio.2009.07.003. Epub 2009 Oct 3.

PMID:
19875045
13.

Imaging in targeted delivery of therapy to cancer.

Dancey G, Begent RH, Meyer T.

Target Oncol. 2009 Sep;4(3):201-17. doi: 10.1007/s11523-009-0119-8. Epub 2009 Oct 8. Review.

PMID:
19838639
14.

Oncology Information Exchange opens up databases.

Begent R.

Lancet Oncol. 2009 Aug;10(8):755. No abstract available.

PMID:
19655433
15.

A phase I trial of radioimmunotherapy with 131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced gastrointestinal carcinomas.

Meyer T, Gaya AM, Dancey G, Stratford MR, Othman S, Sharma SK, Wellsted D, Taylor NJ, Stirling JJ, Poupard L, Folkes LK, Chan PS, Pedley RB, Chester KA, Owen K, Violet JA, Malaroda A, Green AJ, Buscombe J, Padhani AR, Rustin GJ, Begent RH.

Clin Cancer Res. 2009 Jul 1;15(13):4484-92. doi: 10.1158/1078-0432.CCR-09-0035. Epub 2009 Jun 23.

16.

Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors.

Hochhauser D, Meyer T, Spanswick VJ, Wu J, Clingen PH, Loadman P, Cobb M, Gumbrell L, Begent RH, Hartley JA, Jodrell D.

Clin Cancer Res. 2009 Mar 15;15(6):2140-7. doi: 10.1158/1078-0432.CCR-08-1315. Epub 2009 Mar 10.

17.

Data standards for minimum information collection for antibody therapy experiments.

Yong M, Tolner B, Nagl S, Pedley RB, Chester K, Green AJ, Mayer A, Sharma S, Begent R.

Protein Eng Des Sel. 2009 Mar;22(3):221-4. doi: 10.1093/protein/gzp003.

18.

Fibrolamellar hepatocellular carcinoma: prolonged survival with multimodality therapy.

Maniaci V, Davidson BR, Rolles K, Dhillon AP, Hackshaw A, Begent RH, Meyer T.

Eur J Surg Oncol. 2009 Jun;35(6):617-21. doi: 10.1016/j.ejso.2008.12.009. Epub 2009 Jan 13.

PMID:
19144491
19.

Sarcoidosis and testicular cancer: A case series and literature review.

Dick J, Begent RH, Meyer T.

Urol Oncol. 2010 Jul-Aug;28(4):350-4. doi: 10.1016/j.urolonc.2008.09.029. Epub 2008 Dec 12. Review.

PMID:
19070517
20.

Fractionated 131I anti-CEA radioimmunotherapy: effects on xenograft tumour growth and haematological toxicity in mice.

Violet JA, Dearling JL, Green AJ, Begent RH, Pedley RB.

Br J Cancer. 2008 Aug 19;99(4):632-8. doi: 10.1038/sj.bjc.6604511.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk